MedTrace Logo

Safety and Efficacy by Multiple Injection of KH902 in Patients With Diabetic Macular Edema (DME)

NCT01324869 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2013-03-01

No results posted yet for this study

Summary

This study is designed to access the safety and efficacy of multiple injections of KH902 in patients with Diabetic Macular Edema (DME).

Conditions

Interventions

BIOLOGICAL

KH902

Intravitreal injection of 0.5mg/eye/time KH902

Sponsors & Collaborators

  • University of Wisconsin, Madison

    collaborator OTHER

  • Teaching and Research Office of Health Statistics, Fourth Military Medical University

    collaborator UNKNOWN

  • Chengdu Kanghong Biotech Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Xun Xu · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

  • Lun De Luo · Chengdu Kanghong Biotech Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2012-02-29
Completion
2012-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01324869 on ClinicalTrials.gov